

Ref: FOI/GS/ID 5899

**Please reply to:**  
FOI Administrator  
Trust Management  
Maidstone Hospital  
Hermitage Lane  
Maidstone, Kent  
ME16 9QQ  
Email: mtw-tr.foiadmin@nhs.net

24<sup>th</sup> December 2019

## **Freedom of Information Act 2000**

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Breast Cancer treatments.

*You asked:*

*1. Within your health trust how many patients are currently [within the past 3 months] being treated with the following for breast cancer?*

*Abemaciclib + aromatase inhibitor \**

*Abemaciclib + Fulvestrant*

*Alpelisib + Fulvestrant*

*Atezolizumab*

*Bevacizumab*

*Eribulin*

*Everolimus + Exemestane*

*Fulvestrant as a single agent*

*Gemcitabine + paclitaxel*

*Lapatinib*

*Neratinib*

*Olaparib*

*Palbociclib + aromatase inhibitor\**

*Pertuzumab + trastuzumab + docetaxel*

*Ribociclib + aromatase inhibitor\**

*Ribociclib + Fulvestrant*

*Talazoparib*

*Herceptin SC*

*Herceptin IV*

*Transtuzumab biosimilar SC*

*Transtuzumab biosimilar IV*

*Trastuzumab emtansine*

*Other active systemic anti-cancer therapy \*\**

*\*aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole*

*\*\*eg. docetaxel, vinorelbine or capecitabine as a single agent*

2. How many patients are being treated for

2a Neo-adjuvant breast cancer;

Trastuzumab total SC

Trastuzumab total IV

2.b Adjuvant breast cancer;

Trastuzumab total SC

Trastuzumab total IV

Trust response:

Due to the small numbers of cases the Trust has decided that such requests will be answered in bands of 10s.

1.		
Abemaciclib + aromatase inhibitor *		0
Abemaciclib + Fulvestrant		1-10
Alpelisib + Fulvestrant		0
Atezolizumab		1-10
Bevacizumab		0
Eribulin		0
Everolimus + Exemestane		1-10
Fulvestrant as a single agent		1-10
Gemcitabine + paclitaxel		0
Lapatinib		0
Neratinib		0
Olaparib		0
Palbociclib + aromatase inhibitor*		10-20
Pertuzumab + trastuzumab + docetaxel		1-10
Ribociclib + aromatase inhibitor*		1-10
Ribociclib + Fulvestrant		0
Talazoparib		0
Herceptin SC		1-10
Herceptin IV		0
Trastuzumab biosimilar SC		0
Trastuzumab biosimilar IV		0
Trastuzumab emtansine		0
Other active systemic anti-cancer therapy **		30-40
*aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole		
**eg. docetaxel, vinorelbine or capecitabine as a single agent		
2a Neo-adjuvant breast cancer;		
Trastuzumab total SC		0
Trastuzumab total IV		0

2.b Adjuvant breast cancer;		
Transtuzumab total SC		1-10
Transtuzumab total IV		0